Lopez-Tarruella, Sara
Del Monte-Millán, María
Roche-Molina, Marta
Jerez, Yolanda
Echavarria Diaz-Guardamino, Isabel
Herrero López, Blanca
Gamez Casado, Salvador
Marquez-Rodas, Iván
Alvarez, Enrique
Cebollero, María
Massarrah, Tatiana
Ocaña, Inmaculada
Arias, Ainhoa
García-Sáenz, José Ángel
Moreno Anton, Fernando
Olier Garate, Clara
Moreno Muñoz, Diana
Marrupe, David
Lara Álvarez, Miguel Ángel
Enrech, Santos
Bueno Muiño, Coralia
Martín, Miguel http://orcid.org/0000-0001-9237-3231
Article History
Received: 25 January 2023
Accepted: 13 August 2023
First Online: 29 September 2023
Declarations
:
: S.L.–T. received consulting or advisory role fees from AstraZeneca, Novartis, Roche, Pfizer, Pierre Fabre, Lilly, Seagen, Daichii-Sankyo Europe GmbH, Gilead Sciences, MDS, GlaxoSmithKline, and Veracyte and speakers Bureau fees from Lilly. Y.J. received consultant or advisory role fees from Novartis, Pfizer, Roche, and AstraZeneca, she received speaker honoraria from Roche, Novartis, Lilly, and AstraZeneca, and travel and training grants from Roche, Novartis, Pfizer, and Lilly. I.E. received speaker fees from Roche, Teva, Novartis, Pfizer, Lily and advisory role from Lilly and AstraZeneca. T.M. received consulting or advisory boards fees from AstraZeneca, Novartis, Roche, and GSK and travel grants from Novartis and AstraZeneca. J.A.G.-S. received consulting and advisory services fees for Seagen, Gilead, and Sanofi, consultancy/speaker fees from Novartis, Celgene, Eli Lilly, EISAI, AstraZeneca, Daiichi Sankyo, MSD, and Pierre Fabre, institution research funding from AstraZeneca, and travel support from Novartis, Roche, Pfizer. F.M. received consulting or advisory role fees from Roche/Genentech, Novartis, Pfizer, AstraZeneca, MSD, and Daiichi Sankyo/AstraZeneca, speakers’ bureau fees from Pfizer, and travel support from Roche/Genentech, Novartis, and Daiichi Sankyo/AstraZeneca. C. B-M received honoraria as speakers’ honoraria from Roche, Novartis, Lilly, MSD, and AstraZeneca and G.S.K and travel grant from Roche, Novartis, and Pfizer. M.M. received research grants from PUMA; consulting/advisory fees from Roche, Novartis, AstraZeneca, Daiichi Sankyo, Seagen, Lilly, and Sanofi; speakers’ honoraria from Seagen, Lilly, AstraZeneca, Pfizer, Daiichi Sankyo, and Roche. Leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid: Chairman, GEICAM Member of Board of Directors, TRIO. The remaining authors declare no conflict of interest.
: Informed consent was obtained from all individual participants included in the study.
: This study was evaluated and approved by the corresponding Spanish Agency for Medicines and Sanitary Products (AEMPS) on January 16, 2020, in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments.